



November 19, 2024

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

American Heart association – Scientific Session November 18th 2024
-Collategene (HGF gene therapy product)

Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (LEGEND 1 trial), has been chosen to be presented at the (FS.04) Featured Science: Vascular Outcomes in the Spotlight for the American Heart Association's Scientific Sessions 2024, which has taken place in Chicago, IL; USA on Nov. 16-18, 2024. Co- Principal Investigators David G Armstrong DPM, MD, PhD, and Michael S Conte, MD were in attendance representing our clinical trial with Dr. Armstrong presenting the promising top line results.

Detailed results of the clinical trial will be announced after the lead physician's paper is published in a medical journal.

* Founded in 1924 by six cardiologists with the goal of creating a healthier and longer-lived world, the American Heart Association is celebrating its 100th anniversary this year and is one of the world's largest societies in the field of cardiovascular medicine. Since the American Heart Association was founded, deaths from cardiovascular disease have been cut in half. Today the American Heart Association has over 32 million volunteers, donors and supporters.
<https://www.heart.org>